Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.60 |
| ▸ | RECQL | P46063 | 6/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | BLM | P54132 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL18960581 | 1.00 | TDP1 (0.60) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL2688586 | 1.00 | TDP1 (0.60) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL4202261 | 0.88 | TDP1 (0.58) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL18960584 | 0.88 | TDP1 (0.58) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL18960582 | 0.88 | TDP1 (0.58) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL31017988 | 0.88 | TDP1 (0.58) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL18960583 | 0.88 | TDP1 (0.58) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL4202289 | 0.88 | TDP1 (0.58) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| Levodopa SCHEMBL4200978 | 0.86 | KDM4E (0.70) | TDP1KDM4EHSD17B10ALOX15RECQL | |
| SCHEMBL2687611 | 0.85 | KDM4E (0.55) | TDP1KDM4EHSD17B10ALOX15RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165381-A1 | Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease | TEVA PHARMACEUTICALS INT GMBH (CH) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165381-A1 | Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease | COMT, PNMT, THOP1 | DRD3 29/4885TDP1 796/4885KDM4E 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.